Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context

• Үндсэн зохиолчид: Karlijn Verkerk (Зохиогч), Birgit S. Geurts (Зохиогч), Laurien J. Zeverijn (Зохиогч), Vincent van der Noort (Зохиогч), Henk M.W. Verheul (Зохиогч), John B.A.G. Haanen (Зохиогч), Astrid A.M. van der Veldt (Зохиогч), Ferry A.L.M. Eskens (Зохиогч), Maureen J.B. Aarts (Зохиогч), Carla M.L. van Herpen (Зохиогч), Mathilde Jalving (Зохиогч), Jourik A. Gietema (Зохиогч), Lot A. Devriese (Зохиогч), Mariette Labots (Зохиогч), Sahar Barjesteh van Waalwijk van Doorn-Khosrovani (Зохиогч), Egbert F. Smit (Зохиогч), Haiko J. Bloemendal (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Elsevier, 2024-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Summary: Background: The DRUG Access Protocol provides patients with cancer access to registered anti-cancer drugs that are awaiting reimbursement in the Netherlands and simultaneously collects prospective real-world data (RWD). Here, we present RWD from PD-1 blocker cemiplimab in patients with loca...